Curna Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Curna General Information

Description

Developer of drugs. The company engages in developing, manufacturing and marketing of drugs and therapies for commercializing a distinct single-stranded noncoding RNA-based strategy for upregulating gene expression. It primarily manufactures drugs for the treatment of cancer, heart disease, metabolic disorders and genetic anomalies.

Contact Information

Website
www.curna.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 555 Heritage Drive Alexandria Innovation Center
  • Suite 110
  • Jupiter, FL 33458
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Curna Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Curna‘s full profile, request access.

Request a free trial

Curna Patents

Curna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2867262-A1 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf Granted 15-Mar-2012 00000000000
CA-2867262-C Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf Active 15-Mar-2012 00000000000
ES-2694592-T3 Treatment of diseases related to brain-derived neurotrophic factor (bdnf) by inhibition of the natural antisense transcript of bdnf Active 15-Mar-2012 00000000000
US-20150031750-A1 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf Abandoned 15-Mar-2012 00000000000 0
US-20170211071-A1 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf Granted 15-Mar-2012 C12N15/1136 0

Curna Executive Team (2)

Name Title Board Seat Contact Info
Joseph Collard Co-Founder & Chief Executive Officer
Claes Wahlestedt Ph.D Co-Founder
To view Curna’s complete executive team members history, request access »